Luxna Biotech Co., Ltd. is pleased to announce that it has entered into a non-exclusive worldwide license agreement with BioSpring GmbH (Headquarters: Frankfurt, Germany), a global leader in the manufacturing of therapeutic oligonucleotides, for Luxna’s proprietary XNA technology.
For more details, please click here.